Featured Publications
Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention
Seibert T, Garraway I, Plym A, Mahal B, Giri V, Jacobs M, Cheng H, Loeb S, Helfand B, Eeles R, Morgan T. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. European Urology 2023, 83: 241-248. PMID: 36609003, DOI: 10.1016/j.eururo.2022.12.021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTimes higher riskGenetic risk scoreHigh genetic risk scoreLethal prostate cancerProstate cancerHigh genetic riskHigh riskRare pathogenic mutationsHealthy lifestyleEarly detectionPCa riskRisk predictionHigh-grade prostate cancerGenetic riskAggressive prostate cancerProstate cancer riskGenetic risk assessmentDNA damage repair genesGenetic risk predictionPCa mortalityAggressive diseaseLeading causeFamily historyCancer riskElevated risk
2022
Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer
Thakker S, Loeb S, Giri V, Bjurlin M, Matulewicz R. Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer. Urology Practice 2022, 10: 26-32. PMID: 37103438, DOI: 10.1097/upj.0000000000000352.Peer-Reviewed Original ResearchConceptsBreast/ovarian cancerHealth Information National Trends Survey 5Ovarian cancerProstate cancerGenetic testingCancer historyGenetic testing informationHistory of cancerHealthy U.S. adultsExposure of interestHealth care professionalsSelf-reported ratesEvidence-based informationPatient populationRepresentative sampleCare professionalsPatientsSecondary objectiveU.S. adultsCancerCommon sourceCategorical variablesSurvey 5Lack of awarenessCycle 4
2014
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Bancroft E, Page E, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster C, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans D, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney L, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick P, Bojesen A, Skytte A, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams W, Oosterwijk J, Blanco I, Salinas M, Cook J, Rosario D, Buys S, Conner T, Ausems M, Ong K, Hoffman J, Domchek S, Powers J, Teixeira M, Maia S, Foulkes W, Taherian N, Ruijs M, Enden A, Izatt L, Davidson R, Adank M, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman G, Zgajnar J, Tischkowitz M, Clowes V, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady A, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor D, Copakova L, Barwell J, Giri V, Murthy V, Nicolai N, Teo S, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, Collaborators T, Moss S, Eeles R. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology 2014, 66: 489-499. PMID: 24484606, PMCID: PMC4105321, DOI: 10.1016/j.eururo.2014.01.003.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh-risk diseaseBRCA2 mutation carriersProstate cancerTargeted prostate cancerMutation carriersBRCA1/2 mutationsHigh riskProstate-specific antigen (PSA) testingProstate cancer screeningScreening resultsGermline BRCA1/2 mutationsFisher's exact testInitial screening roundGermline genetic markersIdentification of tumorsBreast cancer 1Germline genetic risk variantsBreast cancer 2PCa incidencePSA levelsAntigen testingTumor characteristicsAggressive diseaseBRCA2 carriers
2010
Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val
Giri V, Ruth K, Hughes L, Uzzo R, Chen D, Boorjian S, Viterbo R, Rebbeck T. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val. BJU International 2010, 107: 466-470. PMID: 20735386, PMCID: PMC3052292, DOI: 10.1111/j.1464-410x.2010.09522.x.Peer-Reviewed Original ResearchConceptsHigh-risk menPCa diagnosisCaucasian manElevated prostate-specific antigen concentrationPCa screeningProstate Cancer Risk Assessment ProgramProstate-specific antigen concentrationCancer Risk Assessment ProgramProspective screening cohortCancer diagnosisProspective screening programCT/TTSecond-degree relativesAfrican American menTMPRSS2-ERG fusionUnderwent biopsyScreening cohortStudy entryAA menDegree relativesScreening programBRCA1/2 mutationsSelf-identified raceCox modelGene polymorphisms
2004
Association between Agent Orange and prostate cancer: a pilot case-control study
Giri V, Cassidy A, Beebe-Dimmer J, Ellis L, Smith D, Bock C, Cooney K. Association between Agent Orange and prostate cancer: a pilot case-control study. Urology 2004, 63: 757-760. PMID: 15072895, DOI: 10.1016/j.urology.2003.11.044.Peer-Reviewed Original ResearchMeSH Keywords2,4,5-Trichlorophenoxyacetic Acid2,4-Dichlorophenoxyacetic AcidAgent OrangeCase-Control StudiesDefoliants, ChemicalEnvironmental ExposureHumansMaleMedical Records Systems, ComputerizedMichiganMiddle AgedPilot ProjectsPolychlorinated DibenzodioxinsProstateProstatic NeoplasmsRisk FactorsVeteransVietnamWarfareConceptsCase-control studyProstate cancerPilot case-control studyAgent OrangeVeterans Affairs Medical CenterPilot studyMilitary veteransComputerized medical recordsClinical featuresCancer deathCommon cancerControl menMedical recordsMedical CenterEpidemiologic studiesCancerPrevious exposureAdditional studiesAmerican menClinical populationsMenExposureAssociationAgeVeterans